Annual report pursuant to Section 13 and 15(d)

License Agreements (Details)

v3.23.1
License Agreements (Details)
1 Months Ended 12 Months Ended
Sep. 30, 2015
USD ($)
shares
May 11, 2015
USD ($)
$ / shares
shares
Jun. 30, 2019
USD ($)
May 31, 2016
USD ($)
item
Mar. 31, 2015
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Jan. 31, 2019
USD ($)
NeuPharma, Inc.                
License Agreements                
Payment of upfront licensing fees         $ 1,000,000.0      
NeuPharma, Inc. | Additional sales milestone                
License Agreements                
Maximum potential milestone payments         40,000,000.0      
NeuPharma, Inc. | Clinical and Development Milestone                
License Agreements                
Maximum potential milestone payments         39,000,000.0      
NeuPharma, Inc. | Regulatory Approvals To Commercialize The Products                
License Agreements                
Maximum potential milestone payments         22,500,000      
Dana-Farber Cancer Institute                
License Agreements                
Payment of upfront licensing fees         $ 1,000,000.0      
Number of shares of common stock granted | shares 13,683 50,000            
Value of common stock shares issued $ 600,000 $ 32,500            
Sale price per share | $ / shares   $ 0.65            
Ownership percentage         5.00%      
Cash in exchange for common shares         $ 10,000,000      
Maintenance fee         50,000      
Dana-Farber Cancer Institute | PD-L1                
License Agreements                
Non-Refundable milestone payment             $ 4,000,000.0  
Dana-Farber Cancer Institute | First commercial sale milestone                
License Agreements                
Maximum potential milestone payments         21,500,000      
Dana-Farber Cancer Institute | Additional sales milestone                
License Agreements                
Maximum potential milestone payments         60,000,000.0      
Revenue recognition milestone payments           $ 60,000,000.0    
Jubilant Biosys Limited                
License Agreements                
Payment of upfront licensing fees       $ 2,000,000.0        
Jubilant Biosys Limited | Clinical and Development Milestone                
License Agreements                
Maximum potential milestone payments       88,400,000        
Jubilant Biosys Limited | Regulatory Approvals To Commercialize The Products                
License Agreements                
Maximum potential milestone payments       59,500,000        
Jubilant Biosys Limited | Sale Millstone                
License Agreements                
Maximum potential milestone payments       89,300,000        
Revenue recognition milestone payments       89,300,000        
Adimab, LLC                
License Agreements                
Non-Refundable milestone payment             2,400,000  
Adimab, LLC | Regulatory Approvals To Commercialize The Products                
License Agreements                
Maximum potential milestone payments               $ 4,800,000
Collaboration Agreement With TGTX                
License Agreements                
Revenue recognition milestone revenue recognized           100,000 200,000  
Collaboration Agreement With TGTX | Clinical and Development Milestone | PD-L1 GITR                
License Agreements                
Revenue recognition milestone payments           7,000,000.0    
Collaboration Agreement With TGTX | Commercial Sales In Specified Territories | PD-L1 GITR                
License Agreements                
Maximum potential milestone payments           14,500,000    
Collaboration Agreement With TGTX | Dana-Farber Cancer Institute                
License Agreements                
Proceeds from upfront fees     $ 1,000,000.0   $ 500,000      
Collaboration Agreement With TGTX | Dana-Farber Cancer Institute | First commercial sale milestone | PD-L1                
License Agreements                
Revenue recognition milestone payments           27,600,000    
Collaboration Agreement With TGTX | Dana-Farber Cancer Institute | Clinical and Development Milestone | PD-L1                
License Agreements                
Revenue recognition milestone payments           8,400,000    
Collaboration Agreement With TGTX | Dana-Farber Cancer Institute | Commercial Sales In Specified Territories | PD-L1                
License Agreements                
Revenue recognition milestone payments           19,200,000    
Sublicense Agreement with TGTX | Jubilant Biosys Limited                
License Agreements                
Payment of upfront licensing fees       $ 1,000,000.0        
Revenue recognition milestone revenue recognized           100,000 $ 100,000  
Research and development cost       50.00%        
Number of licensed products | item       2        
Sublicense Agreement with TGTX | Jubilant Biosys Limited | Clinical and Development Milestone                
License Agreements                
Revenue recognition milestone payments       $ 25,500,000        
Number of clinical development milestones | item       3        
Sublicense Agreement with TGTX | Jubilant Biosys Limited | Five Regulatory Approvals And First Commercial Sales                
License Agreements                
Revenue recognition milestone payments       $ 61,900,000        
Sublicense Agreement with TGTX | Jubilant Biosys Limited | Clinical Development and Regulatory Milestones                
License Agreements                
Revenue recognition milestone payments       $ 87,400,000        
Collaboration Agreement With GITR | Dana-Farber Cancer Institute | First commercial sale milestone | PD-L1 GITR                
License Agreements                
Revenue recognition milestone payments           $ 21,500,000